Is ESPR or EVO more undervalued in 2026?

CirclFi compares Esperion Therapeutics, Inc. (ESPR) and Evotec SE (EVO) using 13 institutional-grade valuation models. ESPR has a Quality of Company score of 5.2/10 while EVO scores 6.2/10.

Which is a better buy — ESPR or EVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ESPR and EVO valuations compare?

ESPR at $3.13 and EVO at $2.96 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ESPR vs EVO Valuation Comparison 2026 — Intrinsic Value Analysis

ESPR

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$3.13

Last close

Models

8/13

Active

EVO

Drug Manufacturers - Specialty & Generic

Evotec SE

Quality

6.2

out of 10

Value Trap

SAFE

Price

$2.96

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	ESPR Fair Value	ESPR Upside	EVO Fair Value	EVO Upside
Bayesian DCF	Intrinsic	$1.09	-65.0%	$0.22	-92.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$2.33	-25.7%	$5.88	+96.6%
ML-RIV	Intrinsic	$0.97	-68.9%	$1.12	-62.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ESPR vs EVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ESPR vs EVO — Which Stock Is More Undervalued?

EVO scores higher with a 6.2/10 quality rating vs ESPR's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Esperion Therapeutics, Inc. (ESPR) and Evotec SE (EVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ESPR currently trades at $3.13 with a QOC of 5.2/10, while EVO trades at $2.96 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).